Jagsonpal Pharmaceuticals shareholding pattern

·Pharma & Health Chart ›

Who owns itSep 2026 quarter

Promoters68.81%−0.24 pts

Foreign investors (FII)2.14%−0.16 pts

Domestic institutions (DII)1.65%+1.03 pts

of which mutual funds0.00%no change

Public27.40%

Per cent of all shares; change on the Jun 2026 quarter, in percentage points. As filed with the exchanges.

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

JAGSNPHARM₹230.96

Jagsonpal Pharmaceuticals Limited

· Pharma & Health

₹ CrorePeersAMRUTANJAN NGLFINE SYNCOMF HESTERBIO SIGACHI LINCOLN WINDLASMcap ₹1,547 Cr

Holding % of Total Shares 12 Months Ending	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 02/06/2026	Q1 FY27 30/06/2026	Q2 FY27 30/09/2026
Promoter & Group	67.97	67.81	67.78	67.65	67.54	67.39	67.89	69.36	69.05	68.81
FII / FPI	2.30	2.10	2.10	2.18	2.12	2.12	2.44	2.46	2.30	2.14
DII	0.11	0.00	0.00	0.05	0.09	0.15	0.22	0.31	0.62	1.65
Mutual Funds	0.11	0.00	0.00	—	0.00	0.00	0.00	0.00	0.00	0.00

Latest: 2026-09-30 · 22 quarters of history · click a row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.